Nautilus Biotechnology, Inc.

NasdaqGS NAUT

Nautilus Biotechnology, Inc. Current Liabilities for the quarter ending September 30, 2024: USD 8.66 M

Nautilus Biotechnology, Inc. Current Liabilities is USD 8.66 M for the quarter ending September 30, 2024, a -2.61% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Nautilus Biotechnology, Inc. Current Liabilities for the quarter ending September 30, 2023 was USD 8.89 M, a 38.23% change year over year.
Nautilus Biotechnology, Inc. Current Liabilities for the quarter ending September 30, 2022 was USD 6.43 M, a 52.86% change year over year.
Nautilus Biotechnology, Inc. Current Liabilities for the quarter ending September 30, 2021 was USD 4.21 M.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqGS: NAUT

Nautilus Biotechnology, Inc.

CEO	Mr. Sujal M. Patel
IPO Date	Aug. 7, 2020
Location	United States
Headquarters	2701 Eastlake Avenue East
Employees	161
Sector	Technology
Industries Big Data 3D Printing Biotechnology Credit Cards & Payments Database Fintech Pharmaceuticals

Description

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Key trends

Past 5 years